Stay updated with breaking news from Ersa Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript February 27, 2024 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.31, expectations were $-1.37. Tarsus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
Tarsus Pharmaceuticals, Inc. announced topline results from the Ersa Phase 2a clinical trial evaluating TP-03 administered twice daily or three times a day for 12 weeks for the treatment of Meibomian...
Tarsus Pharmaceuticals, Inc. (TARS) announced Monday positive topline results from the Ersa Phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.
IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. TARS, whose mission is to focus on unmet needs and apply proven science and new…